검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ADT (androgen deprivation therapy, androgen deprivation therapy (ADT)) Istituto Clinico Humanitas·Oligorecurrent and Oligoprogressiv… 72 trials |
|---|---|
Overview Program | androgen deprivation therapy (ADT) |
Overview Company | Istituto Clinico Humanitas |
Overview Modality | ANTIBODY |
Overview Target | Oligorecurrent and Oligoprogressive Pros |
Overview Indication | Oligorecurrent and Oligoprogressive Prostate Cancer Patients |
Overview Phase | PRECLINICAL |
Overview Status | RECRUITING |
MoA Mechanism | targeting Vβ6 and Vβ10 T-cell receptor |
MoA Biomarker | biomarker-driven studies in larger cohorts to refine treatment strategies |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pd |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | SBRT plus abiraterone acetate and ADT versus abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer (ARTO): long-term, unplanned overall survival analysis of an open-label, randomised, phase 2 trial.. The ARTO trial showed improved early clinical outcomes by adding metastasis-directed therapy (MDT), through stereotactic body radiotherapy (SBRT), to abiraterone acetate an… |
Clinical PFS | 0 |
Clinical Result source | ClinicalTrials.gov NCT01531205 |
Clinical Data Tier / Score | A · 29 |
Clinical Program phase | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 12일 (2일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ADT (androgen deprivation therapy, androgen deprivation therapy (ADT)) Istituto Clinico Humanitas·Oligorecurrent and Oligoprogressiv… 72 trials |
|---|---|
Overview Program | androgen deprivation therapy (ADT) |
Overview Company | Istituto Clinico Humanitas |
Overview Modality | ANTIBODY |
Overview Target | Oligorecurrent and Oligoprogressive Pros |
Overview Indication | Oligorecurrent and Oligoprogressive Prostate Cancer Patients |
Overview Phase | PRECLINICAL |
Overview Status | RECRUITING |
MoA Mechanism | targeting Vβ6 and Vβ10 T-cell receptor |
MoA Biomarker | biomarker-driven studies in larger cohorts to refine treatment strategies |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pd |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | SBRT plus abiraterone acetate and ADT versus abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer (ARTO): long-term, unplanned overall survival analysis of an open-label, randomised, phase 2 trial.. The ARTO trial showed improved early clinical outcomes by adding metastasis-directed therapy (MDT), through stereotactic body radiotherapy (SBRT), to abiraterone acetate an… |
Clinical PFS | 0 |
Clinical Result source | ClinicalTrials.gov NCT01531205 |
Clinical Data Tier / Score | A · 29 |
Clinical Program phase | PRECLINICAL |
Clinical Clinical sync | 2026년 7월 12일 (2일 전) |
추천 비교
추천 비교